CN103304424B - 一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂 - Google Patents
一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂 Download PDFInfo
- Publication number
- CN103304424B CN103304424B CN201310274191.6A CN201310274191A CN103304424B CN 103304424 B CN103304424 B CN 103304424B CN 201310274191 A CN201310274191 A CN 201310274191A CN 103304424 B CN103304424 B CN 103304424B
- Authority
- CN
- China
- Prior art keywords
- compound
- injection
- diisopropylamine dichloroacetate
- sunmorl
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940084113 diisopropylamine dichloroacetate Drugs 0.000 title claims abstract description 123
- -1 Diisopropylamine dichloroacetate compound Chemical class 0.000 title claims abstract description 84
- 238000002347 injection Methods 0.000 title claims abstract description 65
- 239000007924 injection Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 150000001875 compounds Chemical class 0.000 title claims abstract description 23
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 14
- 239000001632 sodium acetate Substances 0.000 claims abstract description 14
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 14
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 8
- 239000013078 crystal Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- ILKBHIBYKSHTKQ-UHFFFAOYSA-N Diisopropylamine dichloroacetate Chemical compound OC(=O)C(Cl)Cl.CC(C)NC(C)C ILKBHIBYKSHTKQ-UHFFFAOYSA-N 0.000 claims description 40
- 238000003756 stirring Methods 0.000 claims description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000008215 water for injection Substances 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 17
- 229930195725 Mannitol Natural products 0.000 claims description 17
- 239000000594 mannitol Substances 0.000 claims description 17
- 235000010355 mannitol Nutrition 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000005374 membrane filtration Methods 0.000 claims description 13
- 229960004249 sodium acetate Drugs 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000010792 warming Methods 0.000 claims description 12
- 239000002131 composite material Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 5
- 239000012065 filter cake Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 238000005262 decarbonization Methods 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008176 lyophilized powder Substances 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000000176 sodium gluconate Substances 0.000 abstract 1
- 229940005574 sodium gluconate Drugs 0.000 abstract 1
- 235000012207 sodium gluconate Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
处方 | 1 | 2 |
二氯醋酸二异丙胺 | 20 | 20 |
葡萄糖酸钠 | 19 | 19 |
醋酸钠 | 5 | — |
注射用水加至 | 1000ml | 1000ml |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310274191.6A CN103304424B (zh) | 2013-07-02 | 2013-07-02 | 一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310274191.6A CN103304424B (zh) | 2013-07-02 | 2013-07-02 | 一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103304424A CN103304424A (zh) | 2013-09-18 |
CN103304424B true CN103304424B (zh) | 2014-08-06 |
Family
ID=49130185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310274191.6A Active CN103304424B (zh) | 2013-07-02 | 2013-07-02 | 一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103304424B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104825431A (zh) * | 2015-03-31 | 2015-08-12 | 山东北大高科华泰制药有限公司 | 注射用复方二氯醋酸二异丙胺冷冻干燥粉针剂药物组合物 |
CN115784901A (zh) * | 2022-12-01 | 2023-03-14 | 山东北大高科华泰制药有限公司 | 二氯醋酸二异丙胺及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1568956A (zh) * | 2004-04-28 | 2005-01-26 | 肖广常 | 一种复方二氯醋酸二异丙胺粉针剂 |
CN1596883A (zh) * | 2004-07-19 | 2005-03-23 | 王玫 | 注射用复方二氯醋酸二异丙胺粉针剂及其制备方法 |
-
2013
- 2013-07-02 CN CN201310274191.6A patent/CN103304424B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103304424A (zh) | 2013-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105434373B (zh) | 一种注射用奥拉西坦冻干制剂及其制备方法 | |
CN102351844B (zh) | 泮托拉唑钠化合物及其药物组合物 | |
CN102512383A (zh) | 供注射用的帕瑞昔布钠药物组合物 | |
CN101791310B (zh) | 长春西汀药物组合物及其制备方法 | |
CN103304424B (zh) | 一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂 | |
AU2021269450B2 (en) | Parenteral Formulation comprising Siponimod | |
CN102302461A (zh) | 一种注射用丹曲林钠冻干粉针剂及其制备方法 | |
CN101229133A (zh) | 一种奥美拉唑钠冻干粉针剂及其制备方法 | |
CN102276533B (zh) | 一种新的奥扎格雷钠化合物及其药物组合物 | |
CN102796078B (zh) | 一种泮托拉唑化合物、制备方法及其药物制剂 | |
CN103462910A (zh) | 一种注射用阿奇霉素组合物及其制备方法 | |
CN103159817A (zh) | 一种琥珀酸甲泼尼龙的制备方法 | |
CN103980279B (zh) | 一种甲氨蝶呤化合物及注射用甲氨蝶呤 | |
CN102670524B (zh) | 一种注射用泮托拉唑钠冻干制剂及其制备方法 | |
CN102698253B (zh) | 一种三磷酸腺苷辅酶胰岛素组合物 | |
CN102512382B (zh) | 供注射用埃索美拉唑钠药物组合物 | |
CN104086531B (zh) | 一种埃索美拉唑钠化合物及其药物组合物 | |
CN104922080A (zh) | 治疗消化系统疾病的药物艾普拉唑钠冻干粉针剂组合物 | |
CN103145603B (zh) | 卡络磺钠化合物及其药物组合物 | |
CN102757471B (zh) | 一种新活性三磷酸胞苷二钠化合物及其药物组合物 | |
CN102718693A (zh) | 一种卡络磺钠化合物及其组合物 | |
CN103585119A (zh) | 一种包含依前列醇及其药用盐的稳定化制剂及其制备方法 | |
CN105726495B (zh) | 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法 | |
CN103450086A (zh) | 一种奥扎格雷化合物、制备方法及其药物组合物 | |
CN102600143B (zh) | 长春西汀药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN WUZHOUTONG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUBEI MERRYCLIN PHARMACEUTICALS CO., LTD. Effective date: 20150316 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430014 WUHAN, HUBEI PROVINCE TO: 411200 XIANGTAN, HUNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150316 Address after: 411200 Fenghuang Road, easy Town, Xiangtan County, Xiangtan, Hunan Patentee after: HUNAN WUZHOUTONG PHARMACEUTICAL CO., LTD. Address before: 430014, Zhenghe Plaza, 707 Zhongshan Avenue, Jiang'an District, Hubei, Wuhan, 1506 Patentee before: Hubei Merryclin Pharmaceutical Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Diisopropylamine dichloroacetate compound and compound medicine composition injection thereof Effective date of registration: 20200629 Granted publication date: 20140806 Pledgee: China Construction Bank Corporation Xiangtan County sub branch Pledgor: HUNAN WUZHOUTONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003555 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP03 | Change of name, title or address |
Address after: No. 219, biquantan Road, Tianyi Economic Development Zone, Xiangtan City, Hunan Province Patentee after: Hunan wuzhoutong Pharmaceutical Co., Ltd Address before: 411200 Fenghuang Road, easy Town, Xiangtan County, Xiangtan, Hunan Patentee before: HUNAN WUZHOUTONG PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |